Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Resonance Health Ltd ( (AU:RHT) ) is now available.
Resonance Health Ltd is expanding its TrialsWest business with the opening of a third clinical trial site in Mandurah, Western Australia, expected in August 2025. This expansion is part of the company’s strategy to increase participant capacity and enhance its clinical trial operations, particularly for major pharmaceutical trials. The new site in Mandurah, a rapidly growing city, aligns with the company’s goal to establish trial sites in accessible, densely populated areas with low setup costs, supporting its long-term growth and market positioning.
More about Resonance Health Ltd
Resonance Health Ltd operates in the healthcare industry, focusing on providing medical imaging software and services. The company is known for its clinical trial management through its subsidiary, TrialsWest, which collaborates with pharmaceutical companies to conduct clinical trials.
Average Trading Volume: 218,304
Technical Sentiment Signal: Sell
Current Market Cap: A$18.38M
See more insights into RHT stock on TipRanks’ Stock Analysis page.